Migraine Clinical Trial
Official title:
Effects of Adding an Oculomotor Therapy Treatment to a Cervical Protocol in Patients With Migraine
Verified date | September 2023 |
Source | University of Jaén |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Headaches are the fourth cause/reason for disability in the world population. Of which, headache in general accounts for 47%, 38% are tension headaches, 10% migraines and 3% for chronic headache lasting more than 15 days a month. Migraine is a neurological disease/disorder originating in the central nervous system with difficulty modulating responses to common sensory stimuli. Different studies have linked possible oculomotor problems and headaches, being an important and complex relationship. It is difficult to find a suitable and beneficial treatment for the treatment of migraine. It is hypothesized that adding a treatment of manual therapy and therapeutic exercise of the oculomotor system to an already established protocol of manual therapy and therapeutic exercise of the cervical region, has an additional benefit for patients with migraines (in relation to the quality of life, symptomatology and functionality).
Status | Completed |
Enrollment | 32 |
Est. completion date | September 15, 2023 |
Est. primary completion date | May 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Age between 18-65 years - Suffer less than 15 days of headache per month, - The pain must have these characteristics: unilateral, pulsating, of moderate to severe intensity, during the attack, nausea and/or vomiting, with the possible presence of an aura - History of evolution of more than a year, - Onset and aggravation in the afternoon and - Relation to visual work - Feeling of eye discomfort, - Photophobia - Neck pain after attack. Exclusion Criteria: - Receiving some type of preventive physiotherapy treatment at the time of the intervention - Subjects with preventive medication, pregnancy or lactation, with neurological, systemic or psychiatric disorders, suffering from bone degeneration - Metabolic or musculoskeletal problems that could imply risk of the vertebral artery - Dizziness - Unbalanced tension - Use of specific medication - Lack of fluency in Spanish. |
Country | Name | City | State |
---|---|---|---|
Spain | Physiotherapy clinic | Madrid |
Lead Sponsor | Collaborator |
---|---|
University of Jaén |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in the impact | Using the Headache Impact Test (HIT-6) Questionnaire | Baseline, 6 weeks and 3 months after intervention | |
Secondary | Changes in the pain | Using the Visual Analog Scale (VAS). Each item is scored 0-10 (0= no pain; 10= the major pain that the patient can imagine) yielding a total between 0 and 10. | Baseline, 6 weeks and 3 months after intervention | |
Secondary | Changes in the disability | Using the Migraine Disability Assessment (MIDAS) Questionnaire | Baseline, 6 weeks and 3 months after intervention | |
Secondary | Changes in the depression | Using the Patient Health Questionnaire (PHQ-9) Questionnaire | Baseline, 6 weeks and 3 months after intervention | |
Secondary | Changes in the anxiety | Using the Generalized Anxiety Disorder (GAD-7) Questionnaire | Baseline, 6 weeks and 3 months after intervention | |
Secondary | Changes in the sleep quality | Using the Pittsburgh Sleep Quality Index (PSQI) Questionnaire | Baseline, 6 weeks and 3 months after intervention | |
Secondary | Changes in the kinesiophobia | Using the Tampa Scale of Kinesiophobia (TSK-11) Questionnaire | Baseline, 6 weeks and 3 months after intervention | |
Secondary | Changes in the catastrophizing | Using the Pain Catastrophizing Scale (PCS) Questionnaire | Baseline, 6 weeks and 3 months after intervention | |
Secondary | Changes in the central sensitization | Using the Central Sensitization Inventory (CSI) Questionnaire | Baseline, 6 weeks and 3 months after intervention | |
Secondary | Changes in the neck disability | Using the Neck Disability Index (NDI) Questionnaire | Baseline, 6 weeks and 3 months after intervention | |
Secondary | Changes in the head repositioning | Using the Head Repositioning. This test will be used to assess the subject's proprioceptive ability to reposition the head on the trunk in the horizontal and sagittal planes and to measure the impact of treatment techniques.
The distance between the center of the objective (target) and the laser point is measured, representing the cervico-cephalic positioning error |
Baseline, 6 weeks and 3 months after intervention | |
Secondary | Changes in the strength of the deep cervical flexors | Using the Grimmer Test | Baseline, 6 weeks and 3 months after intervention | |
Secondary | Changes in the ocular movement | Using Smooth tracking test. It consists of following with the eyes an object (stick with a painted dot) that moves in the shape of an "H". | Baseline, 6 weeks and 3 months after intervention | |
Secondary | Changes in the ocular movement with variation of the head | Using the Smooth Pursuit Neck Torsion. It consists of following with the eyes an object (stick with a painted dot) that moves in the shape of an "H" with variant head position | Baseline, 6 weeks and 3 months after intervention | |
Secondary | Changes in the range of movement | Using the Cervical Range of Motion Instrument | Baseline, 6 weeks and 3 months after intervention | |
Secondary | Changes in the quality of life | Using the Short-Form 12 Health Survey (SF-12). Composed of twelve items, eight dimensions (physical function, physical role, bodily pain, mental health, general health, vitality, social function, and emotional role). The score ranges from 0 to 100, where the higher score implies a better health-related quality of life. | Baseline, 6 weeks and 3 months after intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05525611 -
Cabergoline as a Preventive Treatment for Chronic Migraine
|
N/A | |
Completed |
NCT06192173 -
Patent Foramen Ovale Closure in Migraine
|
||
Recruiting |
NCT03832998 -
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
|
Phase 3 | |
Enrolling by invitation |
NCT04196933 -
Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma
|
N/A | |
Not yet recruiting |
NCT06428838 -
Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
|
Phase 3 | |
Completed |
NCT06304675 -
Manageable Environmental Factors in Migraine
|
||
Completed |
NCT04084314 -
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
|
Phase 4 | |
Recruiting |
NCT05517200 -
Pilot Study for a Machine Learning Test for Migraine
|
||
Completed |
NCT04179474 -
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
|
Phase 1 | |
Recruiting |
NCT04603976 -
Registry for Migraine - Clinical Core
|
Phase 4 | |
Completed |
NCT03597529 -
CHOCOlate MeLatonin for AdolescenT MigrainE
|
Phase 2 | |
Completed |
NCT04197349 -
Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman
|
Phase 1 | |
Recruiting |
NCT05891808 -
miR-155 Expression in Episodic and Chronic Migraine
|
||
Active, not recruiting |
NCT05064371 -
Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan
|
Phase 3 | |
Suspended |
NCT04069572 -
Vibratory Stimulation for the Treatment of Chronic Pain
|
N/A | |
Not yet recruiting |
NCT04859374 -
Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach
|
N/A | |
Not yet recruiting |
NCT03083860 -
Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions.
|
N/A | |
Completed |
NCT02905227 -
A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
|
Phase 1 | |
Enrolling by invitation |
NCT02532023 -
The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients
|
Phase 4 | |
Completed |
NCT02108678 -
One-Day Intervention for Depression and Impairment in Migraine Patients
|
N/A |